MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rbr.2015.08.004

Медицинская библиотека · Revista brasileira de reumatologia · 2015

Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.

da Mota Licia Maria Henrique, Cruz Bóris Afonso, de Albuquerque Cleandro Pires, Gonçalves Deborah Pereira, Laurindo Ieda Maria Magalhães, Pereira Ivanio Alves, de Carvalho Jozélio Freire, Pinheiro Geraldo da Rocha Castelar, Bertolo Manoel Barros, Pinto Maria Raquel da Costa, Louzada-Junior Paulo, Xavier Ricardo Machado, Giorgi Rina Dalva Neubarth, Lima Rodrigo Aires Corrêa

СтатьяКлинические рекомендацииОбзорПеревод в очереди

Аннотация

In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database. After this review, a text was produced, answering questions in Pico structure, considering efficacy and safety issues of tofacitinib use for RA treatment in different scenarios (such as first-line treatment after failure with methotrexate [MTX] or other conventional synthetic DMARDs after failure with biological therapy). Based on existing evidence, and considering the available data on efficacy, safety and cost of medications available to treat the disease in Brazil, the RA Commission of SBR, after a process of discussion and voting on proposals, established the following position on the use of tofacitinib for treatment of RA in Brazil: "Tofacitinib, alone or in combination with MTX, is an alternative for RA patients with moderate or high activity after failure of at least two different synthetic DMARDs and one biological DMARD." The level of agreement with this recommendation was 7.5. This position may be reviewed in the coming years, in the face of a greater experience with the use of this medication.

Для цитирования: da Mota Licia Maria Henrique, Cruz Bóris Afonso, de Albuquerque Cleandro Pires, Gonçalves Deborah Pereira, Laurindo Ieda Maria Magalhães, Pereira Ivanio Alves, de Carvalho Jozélio Freire, Pinheiro Geraldo da Rocha Castelar, Bertolo Manoel Barros, Pinto Maria Raquel da Costa, Louzada-Junior Paulo, Xavier Ricardo Machado, Giorgi Rina Dalva Neubarth, Lima Rodrigo Aires Corrêa. Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.. Revista brasileira de reumatologia. 2015. DOI: 10.1016/j.rbr.2015.08.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.